Vanda: FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review

 Vanda Pharmaceuticals Inc. (VNDA) said on Friday that the U.S. Food and Drug Administration (FDA)’s re-review of the clinical hold on long-term clinical studies of Tradipitant in motion sickness has been extended.

The FDA was initially expected to complete the re-review on November 26 and has since then extended it to December 5 to accommodate the leadership shift at the Center for Drug Evaluation and Research, the company said.

https://stocktwits.com/news-articles/markets/equity/vanda-pharmaceuticals-says-fda-will-take-more-time-to-decide-on-tradipitant-clinical-hold-re-review/cL5adTxRELL